Article · 9 Feb 2026
Conference abstractPublished 17 Mar 2021
A Study of the factors associated with the treatment outcome of patients put on Bedaquilline containing treatment regimen for Multi-drug Resistant (MDR) TB
National Institute of Tuberculosis and Respiratory Diseases (NITRD), India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bedaquiline (BDQ) has emerged as new hope in the treatment of MDR TB especially in more complicated cases harboring additional drug resistance such as Fluroroquinolone (FQ) resistance. Wiht its unique mechanism of action whereby it inhibits the Mycobacterial ATP synthase, It promises better success rate for a disease with an otherwise dismal prognosis. NITRD, a tertiary Centre for TB and respiratory diseases was one of the initial sites for implementation of BDQ containing regimens. In our study, we tried to assess the treatment outcome of 43 patients of NITRD which were started on BDQ based regime. Our results showed that more than one-third of the patients (69.8%) had favourable outcome as cure or treatment completed. Unfavourable outcome was mostly associated with increasing age, extensive involvement of Lung parenchyma, addictions (alcoholism, smoking) and concurret Diabetes. Culture conversion time, type of TB, whether Pulmonary or Extra-pulmonary, type of resistance, Second line injectables (SLI) and/or Fluoroquinolone (FQ) and Sputum smear grading were not found to have any association with the treatment outcome of patients on Bedaquiline containing regimen. Our results are encouraging since a good outcome was achieved in patients with more extensive resistace pattern. BDQ has emerged has a potent weapon in the arsenall of anti-tubercular drugs and is now classified in the group A drugs for treatment of MDR TB. Its use is now finding application in national as well as international TB Elimination programmes all around the globe.
Subjects
Pulmonology & RespiratoryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pulmonary & Respiratory Medicine.
Commentary · 29 Dec 2025
Evolving IPF: Personalized Therapies, Future Directions
Brief report · 29 Dec 2025
PH/PAH: Advancements, Guidelines, Future Directions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPulmonary & Respiratory Medicine
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Rupak Singla”
- BylineArticles whose byline prints “Neeta Singla”
